Connectyx Technologies Holdings Group Returns to OTC Current Status

More than $350,000 of Convertible Debt Eliminated
BOCA RATON, FL, April 13, 2020 (GLOBE NEWSWIRE) — Connectyx Technologies Holdings Group (OTC PINK: CTYX) has filed all required annual reports from 2014 through 2019 to become current with its OTC Markets filing requirements.
Due to the extinguishment of convertible debt, the company recorded net income of $331,953 and a substantial decrease in the fully diluted shares outstanding., the Board of Directors has evaluated the current business plan of Connectyx Technologies and have identified significant business opportunities in the Life Sciences sector with an emphasis on bio-pharmaceuticals and medical devices.As previously announced, Paul Michaels, Founder and Managing Director of SunMed Advisors, LLC was appointed Interim CEO and Director of Connectyx Technologies. Mr. Michaels has business and investment experience in Japan and the U.S. with noteworthy expertise in the Life Sciences sector. He has completed transactions involving companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics and Gilead Sciences.Mr. Michaels, Interim CEO of Connectyx, said, “We see real opportunity in building a profitable Life Sciences company via in-licensing, sub-licensing and the marketing of products in the Pharmaceutical and Medical Device field. The Company will focus on promising products with clinical data within the ‘Orphan Disease’ space.”Any specific disease with a patient population numbering less than 200,000 in the United States is considered to be an Orphan Disease.
Michaels continued, “The Company is currently building a new website that will be launched once we have more definitive information available for the investing public. As we move forward, we will continue to update shareholders on corporate developments through Press Releases, Website updates, e-mail communications and public filings.”Investor Database for Future Press Releases and Industry UpdatesInterested investors and shareholders are invited to be added to the corporate e-mail database for corporate press releases and periodic industry updates by sending an e-mail to: investorrelations@connectyx.comAbout Connectyx Technologies Holdings Group, Inc Technologies Holdings Group, Inc. is a global biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined “Orphan Diseases” with patient populations under 200,000 in the United States. The company leverages management’s experience and business relationships with Life Science development associations as well as Life Science-focused venture capital firms to acquire Life Science candidates that fit within the company’s business model.Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CTYX has great potential but is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited to our ability to maintain our website and associated computer systems, our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one of more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.Contact:
Connectyx Technologies Holdings Group, Inc
SunMed Advisors, LLC
Paul Michaels

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.